Samik Pharmaceutical Q1 2026: Consolidated Revenue KRW 15.5B, Net Profit KRW 1.2B; New Drug Approval and Pipeline Strength

Q1 2026 consolidated revenue KRW 15.51B (+10.4% YoY), operating profit KRW 0.93B (-8.5% YoY), net profit KRW 1.24B (+4.3% YoY)
Separate revenue KRW 14.77B (-4.6% YoY), operating profit KRW 0.77B (-24.6% YoY), net profit KRW 0.89B (-55.6% YoY) declined
In Jan 2026, obtained marketing approval for P-CAB gastroesophageal reflux drug 'V-Cap Tab' (launch expected after patent expiry in Nov 2028)
Developing three long-acting injectable pipelines using UniSphero technology (autoimmune, cancer/immuno-adjuvant, obesity)
FY2025 dividend paid: KRW 40 per share cash (total KRW 0.37B); no share buyback or cancellation plans
Debt ratio 23.85%, cash equivalents KRW 4.35B, convertible bonds KRW 2.71B (maturity Mar 2027, conversion price KRW 3,559)
Listed on KOSDAQ in Oct 2025 via SPAC merger; stock split to par value KRW 100
In Nov 2025, received 1-month manufacturing suspension for 17 drugs (ended Jan 2026); in Apr 2026, full conversion of CB (786,176 shares) exercised